TSS
CLVS

Two Sigma Securities’s Clovis Oncology, Inc. CLVS Stock Holding History

Two Sigma Securities’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,500
Closed -$55K – 1927
2020
Q4 		$55K Buy
+11,500
New +$58.2K ﹤0.01% 1551

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Two Sigma Securities's CLVS Position: Q4 2022 in Review

Two Sigma Securities sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 26,054 shares — an estimated $31K sold.

Two Sigma Securities first reported a position in CLVS in Q2 2016 and held it in 9 quarters. The position peaked at $1.04M in Q2 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Two Sigma Securities reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Securities sold 26,054 Clovis Oncology, Inc. shares in Q4 2022, an estimated $31K.
  • Two Sigma Securities first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 9 quarters.
  • Two Sigma Securities's Clovis Oncology, Inc. position peaked at $1.04M in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Two Sigma Securities's 13F filing for Q4 2022, filed 14 Feb 2023.